diabetic gastroparesis, may be linked to upper gastrointestinal symptoms for which current treatment remains suboptimal
The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception
With upwards of 10% of the population affected by diabetes and the enormous attendant costs, a focus on individualising care to make sure that the right person is getting the right therapy at the right time while working to overcome barriers dependent on social determinants of health is essential
Figure 4 Effects on Polycystic Ovary Syndrome Polycystic ovary syndrome (PCOS), which is mainly manifested as sparse ovulation or non-ovulation, high levels of androgens, ovarian polycystic changes, obesity, and infertility, is the most common endocrine and metabolic disorder in women of childbearing age (139)
GLP-1 also suppresses appetite and increases energy expenditure to regulate glucose and energy metabolism [1, 2]
As these innovations progress through clinical development and regulatory approval, they are likely to increase patient adherence, broaden treatment eligibility, and create new commercial opportunities across obesity, diabetes, and other metabolic disorders
